Evidence map›Paper›PMID 40198271›Full record

ArticleJournal of the American Chemical Society2025

High-Throughput Extracellular Vesicle Isolation Using Plate-Based Size Exclusion Chromatography and Automation.

Tal Gilboa, Dmitry Ter-Ovanesyan, Clarissa May Babila, Sara Whiteman, Shad Morton, David Kalish, Jamie Johnston, David Tesin, Matthew Davies, Jenny M Tam and 2 more

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tal GilboaWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.
Dmitry Ter-OvanesyanWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.ORCID 0000-0002-1134-0073
Clarissa May BabilaWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.
Sara WhitemanWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.
Shad MortonWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.
David KalishWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.
Jamie JohnstonCytiva, Cardiff, CF14 7YT, U.K.
David TesinCytiva, Cardiff, CF14 7YT, U.K.
Matthew DaviesCytiva, Cardiff, CF14 7YT, U.K.
Jenny M TamWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.
George M ChurchWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.
David R WaltWyss Institute for Biologically Inspired Engineering, 201 Brookline Ave., Boston, Massachusetts 02215, United States.ORCID 0000-0002-5524-7348

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are natural, cell-derived nanoparticles released into biofluids, such as plasma, and hold great potential as a new class of biomarkers. However, the utility of analyzing EVs in clinical samples has been hampered by a lack of suitable EV isolation methods that can be performed reproducibly in a scalable manner. The current method of choice for isolating EVs, size exclusion chromatography (SEC), is performed manually one column at a time, and thus does not have the throughput for isolating EVs from clinical samples. In this work, we adapt SEC to a plate-based format to increase its throughput. We show that SEC can be performed using plates containing frits packed with resin, where each well of a 24-well plate can be used for a different sample. By measuring EV markers CD63 and CD81, as well as Albumin as a representative free protein, we optimize the separation of EVs from free proteins in the 24-well format. We also demonstrate that performing SEC in these plates can be automated using liquid handling platforms with the use of custom adapters. We quantify the high reproducibility of this automated platform and then apply the platform to analyze the tetraspanins CD63 and CD81 across individuals. Our work represents a solution to the long-standing challenge in the EV biomarker field of reproducible high-throughput EV isolation from plasma and other biofluids. We envision that the automated methods we have developed will scale SEC to hundreds of samples per day, enabling the use of EVs for biomarker discovery and diagnostics.

Indexed as

Chromatography, GelExtracellular VesiclesHigh-Throughput Screening AssaysAutomationHumansTetraspanin 28Tetraspanin 30Tetraspanin 28Tetraspanin 30

Identifiers

PMID40198271
PMCPMC12739687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.